Stefan Loren - Moderna Lead Independent Director

MRNA
 Stock
  

USD 142.85  0.04  0.028%   

  Director
Dr. Stefan D. Loren Ph.D. serves as Lead Independent Director of Marina Biotech Inc. Dr. Loren is currently the founder at Loren Capital Strategy an investment fund. He was previously managing director at Westwicke Partners a healthcarefocused consulting firm from 2008 through February 2014. Dr. Loren has over 20 years of experience as a research and investment professional in the healthcare space including roles at Perceptive Advisors MTB Investment Advisors Legg Mason and Abbott Laboratories. Prior to industry Dr. Loren served as a researcher at The Scripps Research Institute working with Nobel Laureate K. Barry Sharpless on novel synthetic routes to chiral drugs. His scientific work was featured in Scientific American Time Newsweek and Discover as well as other periodicals and journals. Dr. Loren has served as a director of GenVec Inc. since September 2013 and within the past five years he has served on the board of directors of Orchid Cellmark Inc. and PolyMedix Inc
Age: 50  Director Since 2012  Ph.D    
617 714-6500  www.modernatx.com
Loren received a doctorate degree in organic/pharmaceutical chemistry from the University of California at Berkeley and a bachelor’s degree in chemistry from the University of California San Diego.

Moderna Management Efficiency

Moderna has return on total asset (ROA) of 51.93 % which means that it generated profit of $51.93 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 146.08 %, meaning that it created $146.08 on every $100 dollars invested by stockholders. Moderna management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Investment is expected to grow to 162.97. The current year Return on Average Assets is expected to grow to 0.71. Moderna Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 24.67 Billion. The current year Current Assets is expected to grow to about 17.3 B, whereas Tax Assets are forecasted to decline to about 291.7 M.
The company currently holds 916 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Moderna has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Moderna until it has trouble settling it off, either with new capital or with free cash flow. So, Moderna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moderna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moderna to invest in growth at high rates of return. When we think about Moderna's use of debt, we should always consider it together with cash and equity.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people. Moderna (MRNA) is traded on NASDAQ Exchange in USA. It is located in 200 Technology Square, Cambridge, MA 02139, United States and employs 2,700 people. Moderna is listed under Pharmaceutical Products category by Fama And French industry classification.

Moderna Leadership Team

Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vuong Trieu, Chairman of the Board, CFO, Treasurer
Michael French, Chairman, CEO and Pres
Larn Hwang, Chief Scientific Officer
Daniel Geffken, Interim CFO
Erik Emerson, Chief Commercial Officer
Nancy Phelan, Director
Philip Ranker, Director
Joseph Ramelli, Independent Director
Mihir Munsif, COO
Amit Shah, CFO
Tim Boris, Director
Philippe Calais, Director
Donald Williams, Independent Director
Peter Weinstein, Chief Legal Officer
Stefan Loren, Lead Independent Director
Robert Moscato, CEO
Isaac Blech, Director
Eric Teague, CFO
Uli Hacksell, Chairman of the Board

Moderna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
56.8 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.